This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).

Inclusion Criteria: * Signed Informed Consent Form * Able to comply with the study protocol, in the investigator's judgment * Completed the treatment period of Roche sponsored ocrelizumab P-trials Exclusion Criteria: * Hypersensitivity to ocrelizumab or to any of its excipients. * Participantss in a severely immunocompromised state until the condition resolves. * Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation. * Existence of a contra-indication as per SmPC * Prohibited concomitant medication as specified in protocol * Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study